Free Newsletter
Antidepressants show upside in economic downturn
Antidepressants are looking to be big-time recession-busters. In spite of the cost of brand-name meds, Eli Lilly's Cymbalta has grown by leaps and bounds during the economic downturn, with second-quarter sales up by 14 percent year-over-year. And antidepressants in general haven't halted their upward trend, posting $9.6 billion in 2008 sales, up from $9.4 billion in 2007, on 164 million scrips, up from 160 million. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: